Skip to content

Butorphanol-azaperone-medetomidine and ketamine-butorphanol-azaperone-medetomidine chemical immobilization in habituated subadult female giraffe (Giraffa camelopardalis).

Silke Pfitzer, Liesel L Laubscher, Jacobus P Raath, Aleksandr Semjonov, Etienne P Basson, Lisa L Wolfe, Michael W Miller, Gareth E Zeiler

Veterinary anaesthesia and analgesia 2025 DOI: 10.1016/j.vaa.2025.04.009 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Quasi-experimental trial Peer reviewed
Sample size 10
Population Habituated subadult female giraffes
Interventions Butorphanol-azaperone-medetomidine (BAM) Ketamine-butorphanol-azaperone-medetomidine (KBAM)
Dose BAM: 0.02 mL/cm estimated shoulder height; KBAM: 0.015 mL/cm BAM plus 200 mg ketamine
Duration 30 minutes post-recumbency
Topics Esketamine Ketamine
Keywords Kbam Anesthesia-protocols Veterinary-sedation Giraffe-medicine Animal-immobilization
Key findings KBAM produced faster induction than BAM, but both combinations caused clinically significant hypoxaemia in all giraffes.

Abstract

To describe the effects of butorphanol-azaperone-medetomidine (BAM) and ketamine-butorphanol-azaperone-medetomidine (KBAM) used for the chemical immobilization of giraffes. Quasi-experimental trial. A group of 10 habituated subadult female giraffes. Five giraffe were immobilized with BAM (0.02 mL cm-1 estimated shoulder height) and five with KBAM (0.015 mL cm-1 estimated shoulder height BAM and 200 mg ketamine). Time to events were recorded (time to recumbency and recovery time). Physiological variables (heart rate, respiratory rate, rectal temperature, invasive arterial blood pressure and peripheral oxyhaemoglobin saturation) were recorded every 5 minutes and arterial blood gas analysis was performed every 10 minutes after instrumentation. Atipamezole (5 mg mg-1 medetomidine administered) and naltrexone (1 mg mg-1 butorphanol administered) were administered intramuscularly at 30 minutes post-recumbency for recovery. Time to events, physiological and arterial blood gas data were compared between drug combinations using a two-sample t-test (significance was p < 0.05). Data are shown as mean ± standard deviations. All giraffes were successfully immobilized. Based on measured shoulder height, the doses administered were 0.70 and 0.48 mg cm-1 for butorphanol, 0.28 and 0.2 mg cm-1 for azaperone and medetomidine in BAM and KBAM, respectively. Times to recumbency were 17.1 ± 9.3 and 6.3 ± 1.1 minutes for BAM and KBAM respectively (p = 0.06). All giraffes had hypoxaemia and hyperlactataemia, with PaO2 values of 52 ± 13 and 41 ± 4 mmHg and lactate values of 14.4 ± 6.1 and 11.0 ± 5.5 mmol L-1 for BAM and KBAM, respectively. Recoveries were calm with minimal ataxia. BAM and KBAM produced reliable chemical immobilization for 30 minutes. The addition of ketamine to the BAM combination is recommended because of its faster induction time. Because of clinically significant hypoxaemia, oxygen supplementation should be administered if these drug combinations are used.

Comparable studies

Other non-randomized and open-label trials on ketamine, most cited first.

Study Year Design Participants
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Intravenous arketamine for treatment-resistant depression: open-label pilot study Humans with treatment-resistant depression 2020 Open-label pilot trial n = 7
A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide. Hospitalized patients with Major Depressive Disorder and acute suicidal ideation and... 2024 Open label study n = 17
Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research Alcoholic patients 1997 Controlled clinical trial n = 211
Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression Participants with DSM-IV-defined major depressive disorder and treatment-resistant... 2014 Pooled analysis of three clinical trials n = 97

Explore topics